HIV Infections Clinical Trial
Official title:
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir
intraocular device plus oral ganciclovir with respect to efficacy in preventing vision loss.
To compare a treatment regimen that incorporates highly active local therapy (ganciclovir
device) with a treatment regimen that does not.
Cytomegalovirus (CMV) is among the most frequently encountered opportunistic infections in
patients with AIDS. In the era of prophylaxis for pneumocystic pneumonia, CMV disease is
estimated to affect 45 percent of patients with AIDS sometime between the diagnosis of AIDS
and death. Retinitis has been estimated to account for up to 85 percent of CMV disease in
these patients, making CMV retinitis the most common ocular infection encountered. CMV
retinitis is a relatively late-stage manifestation, associated with cluster of
differentiation 4 (CD4) + T-cell counts < 100 cells/µL and often < 50 cells/µL.
All currently available treatments for CMV suppress viral replication but do not eliminate
the virus from the body. Discontinuation of therapy is associated with a prompt relapse of
the retinitis. Despite the use of chronic suppressive therapy, relapse of the retinitis
generally occurs, at least with systemically administered anti-CMV drugs.
The first two treatments approved for CMV retinitis were intravenous ganciclovir and
intravenous foscarnet. Both are given by daily intravenous infusions and therefore require
central venous catheters. The development of newer treatments has focused not only on
efficacious treatments, but also on treatments that do not require central venous catheters.
Available treatments now include oral ganciclovir, the ganciclovir intraocular device, and
intravenous cidofovir.
In vitro data suggest that combination therapies are synergistic in inhibiting viral
replication; these therapies include a foscarnet-ganciclovir combination and a
cidofovir-ganciclovir combination. In the SOCA--CMV Retinitis Retreatment Trial, the
combination of intravenous ganciclovir and foscarnet was more effective than either drug
alone for the treatment of relapsed retinitis. Therefore, the combination of intermittent
intravenous cidofovir and daily oral ganciclovir may be an attractive therapy for relapsed
disease because it may provide synergy for controlling both ocular and visceral disease
while not necessitating either a central venous catheter or an intraocular surgical
procedure.
The Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) is a randomized, multicenter clinical
trial. Patients will be assigned to receive one of two regimens: (1) ganciclovir intraocular
device plus oral ganciclovir or (2) intravenous cidofovir. The intraocular device will be
surgically implanted at baseline and again every 6 to 8 months in eyes with CMV retinitis.
Oral ganciclovir is taken at a dose of 1 gram three times daily. Cidofovir will be
administered intravenously at 5 mg/kg once weekly for 2 consecutive weeks and once every 2
weeks thereafter. If disease progression occurs in patients receiving cidofovir, patients
will be given reinduction therapy, and oral ganciclovir at a dose of 1 gram three times per
day will be added to the treatment. If patients assigned to cidofovir are unable to tolerate
that regimen, an alternative systemic regimen will be recommended.
Study outcome variables include a decrease of three or more lines from baseline in best
corrected visual acuity and rate of visual field loss. The study will also assess other
variables including mortality, blood CMV and HIV load, quality of life, and medical costs.
Treatment assignment will not be masked to either patients or clinicians; however, reading
of fundus photographs to determine both change in retinal involvement and progression will
be masked.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |